delivery route

交货路线
  • 文章类型: Journal Article
    克里米亚-刚果出血热病毒(CCHFV)是一种蜱传播的nairovirus病毒,具有广泛的地理分布,可导致严重和致命的疾病。没有批准具体的医疗对策来对抗这种疾病。CCHFVL蛋白含有具有半胱氨酸蛋白酶的卵巢肿瘤OTU结构域,所述半胱氨酸蛋白酶被认为通过从宿主和病毒蛋白去除泛素和ISG15翻译后修饰来调节细胞免疫应答。病毒去泛素酶如CCHFVOTU是有吸引力的药物靶标,因为阻断它们的活性可能会增强细胞对感染的免疫反应,并可能抑制病毒复制本身。我们先前证明了工程化的泛素变体CC4是体外CCHFV复制的有效抑制剂。小蛋白抑制剂如CC4的治疗用途的主要挑战是它们对细胞内递送的要求。例如,通过病毒载体。在这项研究中,我们研究了复制缺陷型重组腺病毒(Ad-CC4)在致死CCHFV小鼠模型中体内递送CC4的可行性.由于肝脏是CCHFV感染的主要目标,我们旨在通过比较静脉注射(尾静脉)和腹腔注射Ad-CC4来优化对该器官的递送。虽然尾静脉注射是腺病毒递送的传统途径,在我们的手中,腹膜内注射导致腺病毒基因组在组织中更高和更广泛的水平,包括,按照预期,肝脏。然而,尽管有希望的体外结果,两种体内CC4治疗途径均未导致对致死性CCHFV感染的保护作用.
    Crimean-Congo hemorrhagic fever virus (CCHFV) is a tick-borne nairovirus with a wide geographic spread that can cause severe and lethal disease. No specific medical countermeasures are approved to combat this illness. The CCHFV L protein contains an ovarian tumor (OTU) domain with a cysteine protease thought to modulate cellular immune responses by removing ubiquitin and ISG15 post-translational modifications from host and viral proteins. Viral deubiquitinases like CCHFV OTU are attractive drug targets, as blocking their activity may enhance cellular immune responses to infection, and potentially inhibit viral replication itself. We previously demonstrated that the engineered ubiquitin variant CC4 is a potent inhibitor of CCHFV replication in vitro. A major challenge of the therapeutic use of small protein inhibitors such as CC4 is their requirement for intracellular delivery, e.g., by viral vectors. In this study, we examined the feasibility of in vivo CC4 delivery by a replication-deficient recombinant adenovirus (Ad-CC4) in a lethal CCHFV mouse model. Since the liver is a primary target of CCHFV infection, we aimed to optimize delivery to this organ by comparing intravenous (tail vein) and intraperitoneal injection of Ad-CC4. While tail vein injection is a traditional route for adenovirus delivery, in our hands intraperitoneal injection resulted in higher and more widespread levels of adenovirus genome in tissues, including, as intended, the liver. However, despite promising in vitro results, neither route of in vivo CC4 treatment resulted in protection from a lethal CCHFV infection.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    双胎妊娠与母亲和婴儿的不良围产期结局风险较高有关。在双胞胎怀孕后续行动中的许多挑战中,交付方式是最后但不是最不重要的决定,主要影响因素是羊膜性和胎儿表现。该研究的目的是比较两个欧洲中心的围产期结局,在无头第二双胎的情况下,使用不同的双胎分娩方案;意大利患者主要通过剖宫产分娩,比利时患者常规选择阴道分娩(VD)。
    这是一项双中心国际回顾性观察研究。该人群包括843名女性,其双胎妊娠≥32周(双胎或单绒毛膜双胎妊娠)且妊娠结局已知。根据绒毛膜对种群进行分层。每次怀孕报告人口和怀孕数据,而新生儿结局报告为每个胎儿。我们使用多元逻辑回归模型来调整可能的混杂变量,并计算每个孕产妇或新生儿结局的调整后优势比(adjOR)。
    在意大利队列中,观察到的剖宫产率明显更高:绒毛膜妊娠为85%,单绒毛膜妊娠为94.4%,比利时中心分别为45.2%和54.4%(p值<0.001)。我们发现比利时队列显示NICU入院率明显较高,出生时的呼吸窘迫和5分钟后Apgar评分<7。尽管存在这些差异,两组间的复合严重不良结局相似.
    在这项研究中,第二双胞胎的出现和绒毛膜性均不影响孕产妇和严重的新生儿结局,无论两个三级护理中心的分娩方式如何,但VD与较差的短期新生儿结局相关.
    UNASSIGNED: Twin pregnancy is associated with higher risks of adverse perinatal outcomes for both the mother and the babies. Among the many challenges in the follow-up of twin pregnancies, the mode of delivery is the last but not the least decision to be made, with the main influencing factors being amnionicity and fetal presentation. The aim of the study was to compare perinatal outcomes in two European centers using different protocols for twin birth in case of non-cephalic second twin; the Italian patients being delivered mainly by cesarean section with those in Belgium being routinely offered the choice of vaginal delivery (VD).
    UNASSIGNED: This was a dual center international retrospective observational study. The population included 843 women with a twin pregnancy ≥ 32 weeks (dichorionic or monochorionic diamniotic pregnancies) and a known pregnancy outcome. The population was stratified according to chorionicity. Demographic and pregnancy data were reported per pregnancy, whereas neonatal outcomes were reported per fetus. We used multiple logistic regression models to adjust for possible confounding variables and to compute the adjusted odds ratio (adjOR) for each maternal or neonatal outcome.
    UNASSIGNED: The observed rate of cesarean delivery was significantly higher in the Italian cohort: 85% for dichorionic pregnancies and 94.4% for the monochorionic vs 45.2% and 54.4% respectively in the Belgian center (p-value < 0.001). We found that Belgian cohort showed significantly higher rates of NICU admission, respiratory distress at birth and Apgar score of < 7 after 5 min. Despite these differences, the composite severe adverse outcome was similar between the two groups.
    UNASSIGNED: In this study, neither the presentation of the second twin nor the chorionicity affected maternal and severe neonatal outcomes, regardless of the mode of delivery in two tertiary care centers, but VD was associated to a poorer short-term neonatal outcome.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    神经发育是一个高度有组织和复杂的过程,涉及中枢神经系统的持久且通常不可逆的变化。遗传性神经传递障碍(IDNT)是一组遗传性疾病,其中神经传递主要受到影响,导致早期大脑发育异常,表现为神经发育障碍和其他慢性疾病。原则上,IDNT(特别是单基因原因的那些)适合通过精确的遗传校正进行基因替代疗法。然而,基因替代疗法的实际挑战仍然是其从长凳到床边翻译的主要障碍。我们讨论了IDNT基因替代疗法开发的关键考虑因素。作为一个例子,我们描述了我们正在进行的琥珀酸半醛脱氢酶缺乏症基因替代疗法的工作,GABA分解代谢紊乱.
    Neurodevelopment is a highly organized and complex process involving lasting and often irreversible changes in the central nervous system. Inherited disorders of neurotransmission (IDNT) are a group of genetic disorders where neurotransmission is primarily affected, resulting in abnormal brain development from early life, manifest as neurodevelopmental disorders and other chronic conditions. In principle, IDNT (particularly those of monogenic causes) are amenable to gene replacement therapy via precise genetic correction. However, practical challenges for gene replacement therapy remain major hurdles for its translation from bench to bedside. We discuss key considerations for the development of gene replacement therapies for IDNT. As an example, we describe our ongoing work on gene replacement therapy for succinic semialdehyde dehydrogenase deficiency, a GABA catabolic disorder.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    BACKGROUND: Transplantation of neural stem cells improves ischemic stroke outcomes in rodent models and is currently in the clinical test stage. However, the optimal delivery route to achieve improved efficacy remains undetermined.
    OBJECTIVE: This study aims to evaluate three more clinically feasible delivery routes: intravenous (IV), intranasal (IN), and intracerebroventricular (ICV). We compared the therapeutic efficacies of the three routes of transplanting human neural stem cells (hNSCs) into mice with permanent middle cerebral artery obstruction (pMCAO).
    METHODS: Behavioral tests and cresyl violet staining were used to evaluate the therapeutic efficacies of functional recovery and lesion volumes. The expression of proinflammatory cytokines and neurotrophic factors was measured by real-time PCR. The distribution and differentiation of hNSCs were determined by immunofluorescence staining. The effect on endogenous neurogenesis and astrocyte function were determined by immunofluorescence staining and western blot.
    RESULTS: hNSC transplantation using the three routes improved behavioral outcomes and reduced lesion volumes; IV transplantation of hNSCs results in earlier efficacy and improves the inflammatory microenvironment. The long-term distribution and differentiation of transplanted hNSCs in the peri-infarct areas can only be evaluated using ICV delivery. IV and ICV transplantation of hNSCs promote neurogenesis and modulate the dual function of astrocytes in the peri-infarct areas.
    CONCLUSIONS: IV and IN delivery is suitable for repeated administration of hNSCs to achieve improved prognosis. Comparatively, ICV transplantation provides long-term efficacy at lower doses and fewer administration times.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    感觉神经性听力损失(SNHL),一种非常普遍的感觉障碍,遗传和环境因素多方面相互作用的结果。随着我们不断深入了解听觉发育的分子基础和越来越多的耳聋基因汇编,SNHL基因治疗的研究已大大加深。腺相关病毒(AAV),在临床试验中被认为是基因治疗的相对安全的载体,可以基于基因置换等基因治疗策略提供各种转基因,基因沉默,基因编辑,或基因添加以缓解各种类型的SNHL。本文综述了基于AAV的SNHL基因治疗的临床前进展。跨越遗传和后天类型。特别关注双AAV构建方法及其应用,小鼠内耳模型的矢量传递路径(局部,系统性,胎儿,和脑脊液给药),以及从基于AAV的动物模型内耳基因治疗转变为临床实施的重要考虑。
    Sensorineural hearing loss (SNHL), a highly prevalent sensory impairment, results from a multifaceted interaction of genetic and environmental factors. As we continually gain insights into the molecular basis of auditory development and the growing compendium of deafness genes identified, research on gene therapy for SNHL has significantly deepened. Adeno-associated virus (AAV), considered a relatively secure vector for gene therapy in clinical trials, can deliver various transgenes based on gene therapy strategies such as gene replacement, gene silencing, gene editing, or gene addition to alleviate diverse types of SNHL. This review delved into the preclinical advances in AAV-based gene therapy for SNHL, spanning hereditary and acquired types. Particular focus is placed on the dual-AAV construction method and its application, the vector delivery route of mouse inner ear models (local, systemic, fetal, and cerebrospinal fluid administration), and the significant considerations in transforming from AAV-based animal model inner ear gene therapy to clinical implementation.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    目标:HPA轴在婴儿早期编程,但是对于早产或小于胎龄(SGA)儿童的HPA轴编程尚不清楚。因此,这项初步研究的目的是调查早产和出生相关变量对幼儿皮质醇水平的影响。
    方法:在38名早产参与者(妊娠<37周)的横断面设计中测量了皮质醇,年龄在3-9岁之间。通过回归分析研究了早产的相关性(早产程度和分娩途径)与皮质醇水平的关系。
    结果:性别更正,剖腹产与儿童皮质醇水平较低相关(β=-.42,p=.028),解释方差为34%。
    结论:剖腹产分娩途径与早产儿童皮质醇水平降低(或变平)有关。这是临床相关的,可能有重要的影响,因为HPA轴紊乱可能会导致生命后期的发育问题。然而,未来的研究是必要的,以调查进行剖腹产的潜在指征,这将有助于了解影响早产儿童HPA轴发育的因素。
    OBJECTIVE: The HPA-axis is programmed during early infancy, but a lot is unknown about the programming of the HPA-axis in prematurely born or small for gestational age (SGA) children. Therefore, the aim of this preliminary study was to investigate the influence of prematurity and variables associated with birth on cortisol levels in young children.
    METHODS: Cortisol was measured in a cross-sectional design in 38 premature born participants (<37 weeks of gestation), aged between 3 - 9 years old. Correlates of prematurity (degree of prematurity and birth delivery route) were investigated in relationship with cortisol levels with regression analysis.
    RESULTS: Corrected for sex, delivery by C-section was associated with lower cortisol levels in the children (ß = -.42, p = .028), with an explained variance of 34%.
    CONCLUSIONS: Birth delivery route by C-section is associated with lowered (or flattened) cortisol levels in children born prematurely. This is clinically relevant and might have important implications, because an HPA-axis disturbance might lead to developmental problems later on in life. However, future research is necessary to investigate the underlying indications for performing a C-section, which will help to understand factors that influence the HPA-axis development in children born prematurely.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    背景:用于治疗中枢神经系统(CNS)肿瘤的治疗剂穿过血脑屏障(BBB)的有效递送是开发安全和有效疗法的主要挑战。局部区域药物递送平台通过在靶组织中实现高药物浓度而具有可忽略的全身暴露来提供改进的治疗指数。鞘内(心室内)[IT]和对流增强递送[CED]是两种临床相关方法,用于各种CNS恶性肿瘤。这两个独立平台都受到被动的管理后分配力量的影响,有时限制肿瘤治疗所需的分布。聚焦超声和微泡介导的血脑屏障开放(FUS-BBBO)是用于增强药物递送的最新方式。假定FUS与这些替代递送途径的耦合可以提供益处。多模态FUS可以提供在IT施用后增加实质递送深度的所需能力,并且提供CED的轮廓方向性的手段。Further,用FUS-BBBO实现的瞬时增强渗透率是很好的,但是药物的停留时间和运输时间,对临床剂量计划很重要,尚未定义。本调查包括两个离散的研究:1.进行全面的定量评估,以阐明FUS-BBBO的作用,因为它涉及不同的给药途径(IT和IV),以促进药物在纹状体-丘脑区域内的渗透。2.研究FUS-BBBO与CED联用对药物分布的影响,特别关注目标区域内药物滞留的时间动态。
    方法:首先,我们定量评估了FUS-BBBO与IT和IV偶联如何在初始小鼠的预定纹状体-丘脑区域中改变荧光染料(Dextran2000kD和70kDa)的分布和浓度。其次,我们通过测量染料的分布体积和时间依赖性浓度,分析了使用FUS介导的BBB破坏联合CED的药代动力学效应.
    结果:我们的结果表明,与FUS-BBBO偶联的IV给药成功地增强了染料向预定义的超声处理靶标的递送。相反,IT给药后,超声目标中可测量的染料始终较少。FUS增强了CED后染料的分布体积。此外,与单独的CED相比,当CED与FUS-BBBO施用偶联时,观察到更短的停留时间。
    结论:1.根据我们的发现,与IT施用相比,与FUS-BBBO偶联的IV递送是用于递送至预定空间构象内的深靶标(即纹状体-丘脑区域)的更有效的手段。2.FUS-BBBO增加CED给药后染料的分布体积(Vd),但导致更短的停留时间。这一发现是否可与其他类别的试剂重复(例如,细胞毒性剂,抗体,病毒颗粒,细胞疗法)需要研究。
    Efficient delivery of therapeutics across the blood-brain barrier (BBB) for the treatment of central nervous system (CNS) tumors is a major challenge to the development of safe and efficacious therapies. Locoregional drug delivery platforms offer an improved therapeutic index by achieving high drug concentrations in the target tissue with negligible systemic exposure. Intrathecal (intraventricular) [IT] and convection-enhanced delivery [CED] are two clinically relevant methods being employed for various CNS malignancies. Both of these standalone platforms suffer from passive post-administration distribution forces, sometimes limiting the desired distribution for tumor therapy. Focused ultrasound and microbubble-mediated blood-brain barrier opening (FUS-BBBO) is a recent modality used for enhanced drug delivery. It is postulated that coupling of FUS with these alternative delivery routes may provide benefits. Multimodality FUS may provide the desired ability to increase the depth of parenchymal delivery following IT administration and provide a means for contour directionality with CED. Further, the transient enhanced permeability achieved with FUS-BBBO is well established, but drug residence and transit times, important to clinical dose scheduling, have not yet been defined. The present investigation comprises two discrete studies: 1. Conduct a comprehensive quantitative evaluation to elucidate the effect of FUS-BBBO as it relates to varying routes of administration (IT and IV) in its capacity to facilitate drug penetration within the striatal-thalamic region. 2. Investigate the impact of combining FUS-BBBO with CED on drug distribution, with a specific focus on the temporal dynamics of drug retention within the target region.
    Firstly, we quantitatively assessed how FUS-BBBO coupled with IT and IV altered fluorescent dye (Dextran 2000 kDa and 70 kDa) distribution and concentration in a predetermined striatal-thalamic region in naïve mice. Secondly, we analyzed the pharmacokinetic effects of using FUS mediated BBB disruption coupled with CED by measuring the volume of distribution and time-dependent concentration of the dye.
    Our results indicate that IV administration coupled with FUS-BBBO successfully enhances delivery of dye into the pre-defined sonication targets. Conversely, measurable dye in the sonication target was consistently less after IT administration. FUS enhances the distribution volume of dye after CED. Furthermore, a shorter time of residence was observed when CED was coupled with FUS-BBBO application when compared to CED alone.
    1. Based on our findings, IV delivery coupled with FUS-BBBO is a more efficient means for delivery to deep targets (i.e. striatal-thalamic region) within a predefined spatial conformation compared to IT administration. 2. FUS-BBBO increases the volume of distribution (Vd) of dye after CED administration, but results in a shorter time of residence. Whether this finding is reproducible with other classes of agents (e.g., cytotoxic agents, antibodies, viral particles, cellular therapies) needs to be studied.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Review
    未经证实:间充质干细胞(MSCs)是新型的,用于治疗眼表疾病的有前途的药物。MSC可以从几种组织中分离并通过局部或全身途径递送。它们产生几种营养因子和细胞因子,影响免疫调节,转分化,血管生成,以及通过旁分泌在其局部微环境中的促生存途径。此外,他们通过接触依赖的方式发挥治疗作用。
    未经评估:在本次审查中,我们讨论的特点,来源,交货方式,以及MSCs在眼表疾病中的应用。我们还探索了MSCs在抑制眼表衰老方面的潜在应用。
    未经证实:目前正在研究MSCs在眼表疾病中的治疗应用。一个主要的研究领域是角膜上皮病变,包括化学或热烧伤,角膜缘干细胞缺乏症,神经营养性角膜病变,和感染性角膜炎。MSCs可以促进角膜上皮修复并防止不愈合伤口的视觉破坏性后遗症。然而,最佳给药剂量和给药途径尚未确定,需要进一步的临床试验来解决这些基本问题.
    Mesenchymal stem cells (MSCs) are novel, promising agents for treating ocular surface disorders. MSCs can be isolated from several tissues and delivered by local or systemic routes. They produce several trophic factors and cytokines, which affect immunomodulatory, transdifferentiating, angiogenic, and pro-survival pathways in their local microenvironment via paracrine secretion. Moreover, they exert their therapeutic effect through a contact-dependent manner.
    In this review, we discuss the characteristics, sources, delivery methods, and applications of MSCs in ocular surface disorders. We also explore the potential application of MSCs to inhibit senescence at the ocular surface.
    Therapeutic application of MSCs in ocular surface disorders are currently under investigation. One major research area is corneal epitheliopathies, including chemical or thermal burns, limbal stem cell deficiency, neurotrophic keratopathy, and infectious keratitis. MSCs can promote corneal epithelial repair and prevent visually devastating sequelae of non-healing wounds. However, the optimal dosages and delivery routes have yet to be determined and further clinical trials are needed to address these fundamental questions.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    背景:医学文献支持足月臀位计划剖宫产,因为与阴道臀位分娩相比,新生儿发病率和死亡率降低。
    目的:本研究旨在根据两家教学医院的不同分娩方案,比较足月单胎妊娠合并臀位的围产期结局。在常规提供阴道臀位分娩(方案1)或剖宫产(方案2)的情况下,分别。
    方法:2015年1月至2021年5月进行了一项回顾性配对队列研究。共有1079名妇女有资格进行分析。匹配可能的混杂因素后,对每组257例患者进行最终分析.主要结局是产科不良结局和新生儿不良结局的复合。
    结果:总体而言,1079名妇女有资格进行分析。匹配可能的混杂因素后,对每组257例患者进行最终分析.两组产科不良结局的复合相似(24.1%vs24.5%;P=1.000);然而,方案1的新生儿不良结局复合率明显较高(17.9%vs1.2%;P<.001).两组均未报告新生儿死亡或产伤。新生儿重症监护病房的入院率(4.3%vs0.4%;P=0.004),出生时呼吸窘迫(17.5%vs1.2%;P<.001),5分钟后Apgar评分<7(5.8%vs0.4%;P<.001)明显高于方案1。
    结论:短期,方案1组的非严重不良新生儿结局显著增加.这些必须与剖宫产对长期婴儿和产妇健康可能产生的负面影响相平衡。
    BACKGROUND: Medical literature supports planned cesarean delivery for breech presentation at term because of observed reductions in neonatal morbidity and mortality compared with vaginal breech delivery.
    OBJECTIVE: This study aimed to compare perinatal outcomes of singleton pregnancies with breech presentation at term according to the different delivery protocols of 2 teaching hospitals, where vaginal breech delivery (protocol 1) or cesarean delivery (protocol 2) is routinely offered, respectively.
    METHODS: A retrospective matched cohort study was conducted between January 2015 and May 2021. A total of 1079 women were eligible for analysis. After matching for possible confounding factors, the final analysis was performed on 257 patients in each group. The primary outcomes were a composite of adverse obstetrical outcomes and a composite of neonatal adverse outcomes.
    RESULTS: Overall, 1079 women were eligible for analysis. After matching for possible confounding factors, the final analysis was performed on 257 patients in each group. The composite of adverse obstetrical outcomes was similar in the 2 groups (24.1% vs 24.5%; P=1.000); however, the composite of neonatal adverse outcomes was significantly higher for protocol 1 (17.9% vs 1.2%; P<.001). No neonatal death or birth trauma was reported in either group. The rates of neonatal intensive care unit admission (4.3% vs 0.4%; P=.004), respiratory distress at birth (17.5% vs 1.2%; P<.001), and Apgar scores of <7 after 5 minutes (5.8% vs 0.4%; P<.001) were significantly higher for protocol 1.
    CONCLUSIONS: Short-term, nonsevere adverse neonatal outcomes were significantly increased in the protocol 1 group. These must be balanced against the possible negative effects of cesarean delivery on long-term infant and maternal health.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    在过去两年中,mRNA疫苗在抗击COVID-19大流行方面具有革命性。它们也已成为预防传染病和治疗癌症的通用工具。为了有效的疫苗接种,mRNA配方,mRNA载体的传递方法和组成起着重要的作用。mRNA疫苗可以使用脂质纳米颗粒递送,聚合物,肽或裸mRNA。疫苗效力受合适的递送材料的影响,制剂方法和选择合适的给药途径。此外,几种mRNA的共同递送也可能是有益的,并且增强针对感染性病原体的各种变体或几种病原体的免疫力。这里,我们回顾了交货方法的最新进展,交付方式和可获得专利的mRNA疫苗技术。
    mRNA vaccines have been revolutionary in combating the COVID-19 pandemic in the past two years. They have also become a versatile tool for the prevention of infectious diseases and treatment of cancers. For effective vaccination, mRNA formulation, delivery method and composition of the mRNA carrier play an important role. mRNA vaccines can be delivered using lipid nanoparticles, polymers, peptides or naked mRNA. The vaccine efficacy is influenced by the appropriate delivery materials, formulation methods and selection of a proper administration route. In addition, co-delivery of several mRNAs could also be beneficial and enhance immunity against various variants of an infectious pathogen or several pathogens altogether. Here, we review the recent progress in the delivery methods, modes of delivery and patentable mRNA vaccine technologies.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

公众号